Open AccessBioequivalence assessment of BCD-022 (trastuzumab, manufactured by JSC BIOCAD, Russia) as compared with Herceptin® (F.Hoffmann-La Roche Ltd., Switzerland), used in combination with paclitaxel in HER2-positive metastatic breast cancer patients:
Author(s) -
Ekaterina Ignatova,
Olga Burdaeva,
Mikhail V. Kopp
Publication year - 2016
Publication title -
sovremennaâ onkologiâ
Language(s) - English
Resource type - Journals
eISSN - 1815-1442
pISSN - 1815-1434
DOI - 10.26442/1815-1434_2016.2.39-47
Subject(s) - trastuzumab , bioequivalence , medicine , paclitaxel , oncology , metastatic breast cancer , breast cancer , cancer , gynecology , pharmacokinetics